Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia

被引:111
作者
Jumaa, H
Bossaller, L
Portugal, K
Storch, B
Lotz, M
Flemming, A
Schrappe, M
Postila, V
Riikonen, P
Pelkonen, J
Niemeyer, CM
Reth, M [1 ]
机构
[1] Univ Freiburg, D-79108 Freiburg, Germany
[2] Max Planck Inst Immunobiol, D-79108 Freiburg, Germany
[3] Med Sch Hanover, Childrens Hosp, D-30625 Hannover, Germany
[4] Univ Kuopio, Dept Clin Microbiol, FIN-70211 Kuopio, Finland
[5] Kuopio Univ Hosp, Dept Clin Microbiol, FIN-70211 Kuopio, Finland
[6] Kuopio Univ Hosp, Dept Pediat, FIN-70211 Kuopio, Finland
[7] Freiburg Univ Hosp, Dept Pediat & Adolescent Med, Div Pediat Hematol & Oncol, D-79106 Freiburg, Germany
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nature01608
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Acute lymphoblastic leukaemia (ALL) is the commonest form of childhood malignancy, and most cases arise from B-cell clones arrested at the pre-B-cell stage of differentiation(1,2). The molecular events that arrest pre-B-cell differentiation in the leukaemic pre-B cells have not been well characterized. Here we show that the differentiation regulator SLP-65 (an adaptor protein also called BLNK or BASH(3-6)) inhibits pre-B-cell leukaemia in mice. Reconstitution of SLP-65 expression in a SLP-65(-/-) pre-B-cell line led to enhanced differentiation in vitro and prevented the development of pre-B-cell leukaemia in immune-deficient mice. Tyrosine 96 of SLP-65 was required for this activity. The murine SLP-65(-/-) pre-B-cell leukaemia resembles human childhood pre-B ALL. Indeed, 16 of the 34 childhood pre-B ALL samples that were tested showed a complete loss or drastic reduction of SLP-65 expression. This loss is probably due to the incorporation of alternative exons into SLP-65 transcripts, leading to premature stop codons. Thus, the somatic loss of SLP-65 and the accompanying block in pre-B-cell differentiation might be one of the primary causes of childhood pre-B ALL.
引用
收藏
页码:452 / 456
页数:6
相关论文
共 29 条
[1]   Bcr-Abl variants:: biological and clinical aspects [J].
Advani, AS ;
Pendergast, AM .
LEUKEMIA RESEARCH, 2002, 26 (08) :713-720
[2]   MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia [J].
Armstrong, SA ;
Staunton, JE ;
Silverman, LB ;
Pieters, R ;
de Boer, ML ;
Minden, MD ;
Sallan, SE ;
Lander, ES ;
Golub, TR ;
Korsmeyer, SJ .
NATURE GENETICS, 2002, 30 (01) :41-47
[3]  
BEISHUIZEN A, 1991, LEUKEMIA, V5, P657
[4]   BLNK:: molecular scaffolding through 'cis'-mediated organization of signaling proteins [J].
Chiu, CW ;
Dalton, M ;
Ishiai, M ;
Kurosaki, T ;
Chan, AC .
EMBO JOURNAL, 2002, 21 (23) :6461-6472
[5]   LYMPHOID DEVELOPMENT IN MICE WITH A TARGETED DELETION OF THE INTERLEUKIN-2 RECEPTOR-GAMMA CHAIN [J].
DISANTO, JP ;
MULLER, W ;
GUYGRAND, D ;
FISCHER, A ;
RAJEWSKY, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (02) :377-381
[6]   ACUTE MIXED-LINEAGE LEUKEMIA T(4-11)(Q21-Q23) GENERATES AN MLL-AF4 FUSION PRODUCT [J].
DOMER, PH ;
FAKHARZADEH, SS ;
CHEN, CS ;
JOCKEL, J ;
JOHANSEN, L ;
SILVERMAN, GA ;
KERSEY, JH ;
KORSMEYER, SJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (16) :7884-7888
[7]  
EDERY I, 1983, J BIOL CHEM, V258, P1398
[8]   The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion [J].
Flemming, A ;
Brummer, T ;
Reth, M ;
Jumaa, H .
NATURE IMMUNOLOGY, 2003, 4 (01) :38-43
[9]   BLNK: a central linker protein in B cell activation [J].
Fu, C ;
Turck, CW ;
Kurosaki, T ;
Chan, AC .
IMMUNITY, 1998, 9 (01) :93-103
[10]  
Goitsuka R, 1998, J IMMUNOL, V161, P5804